CRISPR Therapeutics AG - Common Shares (CRSP)

The company's strong cash position gives investors confidence in the gene-editing stock.

Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor.

The gene-editing stock has been in a tailspin of late.

As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant dominated the CF landscape with its groundbreaking CFTR modulators, but today, the narrative has shifted to a broader multi-disease platform. With the successful 2025 launch of [...]

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

They're names worth holding for far longer, but the coming decade could prove particularly fruitful for these companies.

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031.

The firm believes the new lineup could significantly expand Rivian's addressable EV market.

These two biotechs have a lot in common. Their differences are even more pronounced.

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.

Could these three stocks be Cathie Wood's next big winners?

The past few years have been challenging for the biotech.

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

These biotech companies have catalysts ahead.

The company could finally be ready to deliver on years of promise.

2026 could be a big year for this company.

A sales partner offered a ray of hope that this company couldn't for itself.

Opportunity knocks thrice for the iconic growth investor.

Artificial intelligence (AI) isn't the only industry with explosive growth potential.

Retail sentiment on major ETFs such as SPY and QQQ remains ‘extremely bearish’ on Stocktwits.

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core products.

And, if all goes well, over the next five years as well.